R&D Call: Deucrictibant: Beyond HAE-1/2

Jun 4, 2025 8:00 AM EDT

The virtual event will explore the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment paradigm and unmet needs of those living with bradykinin-mediated angioedema, the potential of deucrictibant to address those unmet needs, and Pharvaris’ biomarker approach to identification of those living with bradykinin-mediated angioedema and other diseases. Presenters of the event are:

  • Danny M. Cohn, M.D., Ph.D., Department of Vascular Medicine, Amsterdam UMC (an accredited center of ACARE)
  • Anne Lesage, Ph.D., Chief Early Development Officer, Pharvaris
  • Peng Lu, M.D., Ph.D., Chief Medical Officer, Pharvaris
  • Berndt Modig, Chief Executive Officer, Pharvaris

Supporting Materials